Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL
Status:
Not yet recruiting
Trial end date:
2041-06-01
Target enrollment:
Participant gender:
Summary
This is a phase I, open label study to evaluate the safety, identify the recommended dose
(RD) and obtain preliminar evidence of the efficacy of allogeneic, CD19-directed Chimeric
Antigen Receptor T (alloCAR-T) cells in pediatric and young adults patients with
relapsed/refractory B-cell precursor Acute Lymphoblastic Leukemia (BCP-ALL).